Linda Yau - Concepedia

Author

Linda Yau

Research Triangle Park Foundation

Also Known As

LINDA YAU, Linda Yau, Yau Linda

Publications

Citations

H-Index

Concepts

All Affiliations

Research Triangle Park Foundation GlaxoSmithKline (United States)Orlando Immunology Center George Washington University Sidney Kimmel Cancer Center

About

Linda Yau is an author at Research Triangle Park Foundation specializing in medicine, virology, and clinical trials.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	406
2	Health Sciences	1	1	30
3	Public Health	1	1	383
4	Biostatistics	1	1	383
5	Emergency Medicine	1	1	25

Linda Yau

Publications

Citations

H-Index

Page 1

	Year	Citations
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia Carlos Salama, Jian Han, Linda Yau, New England Journal of Medicine	2020	1.3K
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer Fotios Loupakis, Dongyun Yang, Linda Yau, JNCI Journal of the National Cancer Institute	2015	489
Intent-to-Treat Analysis for Longitudinal Studies with Drop-Outs Roderick J. A. Little, Linda Yau Biometrics Imputation DifferHealth PolicyLongitudinal Data AnalysisClinical TrialsTreatment Effect	1996	383
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial Joseph J. Eron, Patrick Yéni, Joseph Gathe, The Lancet Klean StudyTreatment And PreventionHiv InfectionClinical TrialsAntiviral Drug Development	2006	341
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment Kimberly Y. Smith, Parul Patel, Derek M. Fine, AIDS	2009	217
MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Aparna R. Parikh, Fa-Chyi Lee, Linda Yau, Clinical Cancer Research	2018	60
MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). Heinz‐Josef Lenz, Fa-Chyi Lee, Linda Yau, Journal of Clinical Oncology PathologyCt BackboneOncologyGastrointestinal OncologyMetronomic Therapy	2016	30
Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study Richard Elion, Edwin DeJesus, Michael Sension, HIV Clinical Trials	2008	28
Tocilizumab in nonventilated patients hospitalized with Covid-19 pneumonia Carlos Salama, Jian Han, Linda Yau, Nonventilated PatientsCovid-19 PandemicRespiratory InfectionInfectious Respiratory DiseasePlacebo Arms	2020	25
A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1–Infected Patients: 48-Week Results of the SHIELD Trial Benjamin Young, Thanes Vanig, Edwin DeJesus, HIV Clinical Trials	2010	21

Page 1